Greg Yap is listed as a director on 18 SEC Form D filings by 6 issuers between Oct 2018 and Dec 2025. Largest by amount reported sold: Delfi Diagnostics, Inc. (Palo Alto, CA — biotechnology — 2019–2025; $225M reported sold to 50 investors), H1 Insights, Inc. (New York, NY — industry reported as "Other" — 2020–2024; $121M reported sold to 68 investors), Clear Labs, Inc. (San Carlos, CA — biotechnology — 2018–2024; $60M reported sold to 33 investors), Ophelia Health, Inc. (New York, NY — industry reported as "Other" — 2021; $50M reported sold to 27 investors), Particle Health Inc. (New York, NY — other technology — 2020–2022; $24M reported sold to 19 investors) and 1 more (all listed below).
What this means A repeat sponsor — 6 separate companies raised money with this person listed as director, over about 7 years. Across those companies the filings report $492.5M sold in total.
Listed alongside Ariel Katz (4 shared filings), Gaurav Garg (4 shared filings), Ian Sax (4 shared filings), Mostafa Ronaghi (4 shared filings), Sasan Amini (4 shared filings) and 40 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Greg. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 18 public filings for Greg Yap and found 10 differences: 6 Form Ds were filed more than 15 days after the first sale; Offering amount changed between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.